89Zr-labeled paramagnetic octreotide-liposomes for PET-MR imaging of cancer

Pharmaceutical Research

Volumn 30, Issue 3, 2013, Pages 878-888

  Abou, Diane S ^a   Thorek, Daniel L J ^a   Ramos, Nicholas N ^a   Pinkse, Martijn W H ^b   Wolterbeek, Hubert T ^b   Carlin, Sean D ^a   Beattie, Bradley J ^a   Lewis, Jason S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b DELFT UNIVERSITY OF TECHNOLOGY   (Netherlands)

Author keywords

89Zr; nanoparticles; octreotide; PET MRI; targeted molecular imaging

Indexed keywords

1,2 DISTEAROYL SN GLYCERO 3 PHOSPHOCHOLINE; CONTRAST MEDIUM; GADOLINIUM; GADOLINIUM LIPOSOME ZIRCONIUM 89 CONJUGATE; LIPOSOME; LIPOSOME OCTREOTIDE CONJUGATE; LIPOSOME ZIRCONIUM 89 CONJUGATE; OCTREOTIDE; PARAMAGNETIC OCTREOTIDE; PHOSPHORYLCHOLINE; RADIOPHARMACEUTICAL AGENT; SOMATOSTATIN RECEPTOR 2; UNCLASSIFIED DRUG; ZIRCONIUM 89;

ADSORPTION KINETICS; ANIMAL CELL; ARTICLE; CANCER DIAGNOSIS; CONTROLLED STUDY; DIAGNOSTIC IMAGING; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MALIGNANT NEOPLASTIC DISEASE; NEUROENDOCRINE TUMOR; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHYSICAL CHEMISTRY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS;

ANIMALS; CELL LINE, TUMOR; CONTRAST MEDIA; GADOLINIUM; HUMANS; ISOTOPES; LIPOSOMES; MAGNETIC RESONANCE IMAGING; MICE; NEUROENDOCRINE TUMORS; OCTREOTIDE; POSITRON-EMISSION TOMOGRAPHY; RECEPTORS, SOMATOSTATIN; ZIRCONIUM;

EID: 84878893321     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-012-0929-8     Document Type: Article

References (30)

1. Cherry SR. Multimodality imaging: beyond PET/CT and SPECT/CT. Semin Nucl Med. 2009;39(5):348-53. Epub 2009/08/04.
2. Catana C, Procissi D, Wu Y, Judenhofer MS, Qi J, Pichler BJ, et al. Simultaneous in vivo positron emission tomography and magnetic resonance imaging. Proc Natl Acad Sci U S A. 2008;105(10):3705-10. Epub 2008/03/06.
3. Bellin MF. MR contrast agents, the old and the new. Eur J Radiol. 2006;60(3):314-23. Epub 2006/09/29.
4. Shellock FG. MR imaging in patients with intraspinal bullets. J Magn Reson Imaging. 1999;10(1):107. Epub 1999/07/10.
5. Terreno E, Delli Castelli D, Cabella C, Dastru W, Sanino A, Stancanello J, et al. Paramagnetic liposomes as innovative contrast agents for magnetic resonance (MR) molecular imaging applications. Chem Biodivers. 2008;5(10):1901-12. Epub 2008/10/31.
6. Soret M, Bacharach SL, Buvat I. Partial-volume effect in PET tumor imaging. J Nucl Med. 2007;48(6):932-45. Epub 2007/05/17.
7. Phillips WT, Goins BA, Bao A. Radioactive liposomes. Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2009;1(1):69-83. Epub 2010/01/06.
8. Holland JP, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. 89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med. 2010;51(8):1293-300. Epub 2010/07/28.
9. Laverman P, Boerman OC, Oyen WJG, Corstens FHM, Storm G. In vivo applications of PEG liposomes: unexpected observations. Crit Rev Ther Drug Carrier Syst. 2001;18(6):551-66. Epub 2002/01/16.
10. ElBayoumi TA, Torchilin VP. Tumor-targeted nanomedicines: enhanced antitumor efficacy in vivo of doxorubicin-loaded, long-circulating liposomes modified with cancer-specific monoclonal antibody. Clin Cancer Res. 2009;15(6):1973-80. Epub 2009/03/12.
11. Iwase Y, Maitani Y. Octreotide-targeted liposomes loaded with CPT-11 enhanced cytotoxicity for the treatment of medullary thyroid carcinoma. Mol Pharm. 2011;8(2):330-7. Epub 2010/12/21.
12. Iwase Y, Maitani Y. Dual functional octreotide-modified liposomal irinotecan leads to high therapeutic efficacy for medullary thyroid carcinoma xenografts. Cancer Sci. 2012;103(2):310-6.
13. Reubi JC. Peptide receptors as molecular targets for cancer diagnosis and therapy. Endocr Rev. 2003;24(4):389-427. Epub 2003/08/16.
14. Sun M, Wang Y, Shen J, Xiao Y, Su Z, Ping Q. Octreotide-modification enhances the delivery and targeting of doxorubicin-loaded liposomes to somatostatin receptors expressing tumor in vitro and in vivo. Nanotechnology. 2010;21(47):475101. Epub 2010/10/30.
15. Holland JP, Sheh Y, Lewis JS. Standardized methods for the production of high specific-activity zirconium-89. Nucl Med Biol. 2009;36(7):729-39. Epub 2009/09/02.
16. Stewart JC. Colorimetric determination of phospholipids with ammonium ferrothiocyanate. Anal Biochem. 1980;104(1):10-4. Epub 1980/05/01.
17. Medina OP, Pillarsetty N, Glekas A, Punzalan B, Longo V, Gonen M, et al. Optimizing tumor targeting of the lipophilic EGFR-binding radiotracer SKI 243 using a liposomal nanoparticle delivery system. J Control Release. 2011;149(3):292-8. Epub 2010/11/05.
18. Barlow DJ, Hollinshead CM, Harvey RD, Webster JRP, Hughes AV, Weston A, et al. Effects of surface pressure on the structure of distearoylphosphatidylcholine monolayers formed at the air/water interface. Langmuir. 2009;25(7):4070-7.
19. Abou DS, Ku T, Smith-Jones PM. In vivo biodistribution and accumulation of 89Zr in mice. Nucl Med Biol. 2011;38(5):675-81. Epub 2011/07/02.
20. Enoch HG, Strittmatter P. Formation and properties of 1000-A-diameter, single-bilayer phospholipid vesicles. Proc Natl Acad Sci U S A. 1979;76(1):145-9. Epub 1979/01/01.
21. Zhang H, Moroz MA, Serganova I, Ku T, Huang R, Vider J, et al. Imaging expression of the human somatostatin receptor subtype-2 reporter gene with 68 Ga-DOTATOC. J Nucl Med. 2011;52(1):123-31. Epub 2010/12/15.
22. Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol. 1986;31(4):229-34. Epub 1986/04/01.
23. Beattie BJ, Forster GJ, Govantes R, Le CH, Longo VA, Zanzonico PB, et al. Multimodality registration without a dedicated multimodality scanner. Mol Imaging. 2007;6(2):108-20. Epub 2007/04/21.
24. Na DH, Murty SB, Lee KC, Thanoo BC, DeLuca PP. Preparation and stability of poly(ethylene glycol) (PEG)ylated octreotide for application to microsphere delivery. AAPS PharmSciTech. 2003;4(4):E72. Epub 2004/06/17.
25. Strijkers GJ, Mulder WJ, van Heeswijk RB, Frederik PM, Bomans P, Magusin PC, et al. Relaxivity of liposomal paramagnetic MRI contrast agents. MAGMA. 2005;18(4):186-92. Epub 2005/09/13.
26. Dijkers EC, Oude Munnink TH, Kosterink JG, Brouwers AH, Jager PL, de Jong JR, et al. Biodistribution of 89Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with metastatic breast cancer. Clin Pharmacol Ther. 2010;87(5):586-92. Epub 2010/04/02.
27. Fabre RM, Talham DR. Stable supported lipid bilayers on zirconium phosphonate surfaces. Langmuir. 2009;25(21):12644-52. Epub 2009/08/29.
28. Maeda H, Wu J, Sawa T, Matsumura Y, Hori K. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release. 2000;65(1-2):271-84. Epub 2000/03/04.
29. Beschiaschvili G, Seelig J. Peptide binding to lipid bilayers. Nonclassical hydrophobic effect and membrane-induced pK shifts. Biochemistry. 1992;31(41):10044-53. Epub 1992/10/20.
30. Ahrens ET, Rothbacher U, Jacobs RE, Fraser SE. A model for MRI contrast enhancement using T1 agents. Proc Natl Acad Sci U S A. 1998;95(15):8443-8. Epub 1998/07/22.